Company intelligence / Profile preview

Bolden Therapeutics

Providence, Rhode Island, United Statesboldentherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Bolden Therapeutics has demonstrated proof-of-concept in proprietary mouse models showing increased neurogenesis and improved hippocampal-dependent memory by modulating a novel signaling pathway with exon-skipping antisense oligonucleotides. The company has received NIH/NIA SBIR/STTR grants to advance these candidates toward clinical development for Alzheimer’s disease and related CNS disorders. Human clinical trials have not yet begun.

Therapeutic areas: NeurologyCardiovascular
Modalities: Antisense oligonucleotide
Industry: Biotech

Drug pipeline

2 assets

bdnf antisense oligonucleotide

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Biogen (“Golden Ticket” incubator sponsorship at LabCentral/Kendall Square Cambridge MA lab space support)

Beyond the preview

Go deeper on Bolden Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bolden Therapeutics.

Explore the full profile